ABCC4 , ABCC5 and SLC28A1 Polymorphisms: Host Genome on Responses of Chronic Hepatitis B Patients with Entecavir Treatment
Authors:
- 1 November 2015
- journal article
- research article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 21 (8) , 689-696
Abstract
Background: Nucleoside drug transporter polymorphisms play a significant role in patient responses to drugs. The aim was to investigate the effect of multi-drug resistance protein 4, multi-drug resistance protein 5 and human concentrative nucleoside transporter 1 gene polymorphisms on the response to entecavir treatment in chronic hepatitis B patients. Methods: A total of 324 chronic HBV treatment-naive Chinese Han patients treated with entecavir 0.5 mg daily for 1 year were enrolled. Patients were divided into a response group and non-response group according to the decline of HBV DNA levels. A multiplex SNaPshot single-base extension method was designed for genotyping. Results: The rs3751333GG genotype of multi-drug resistance protein 4 was significantly different between the response group and non-response group at 6 and 12 months ( P=0.005 and P=0.019, respectively). Multivariate analysis showed that the rs37751333GG genotype was significantly associated with responses at 6 and 12 months (odds ratio 2.630, 95% CI 1.391, 4.974, P=0.003; odds ratio 2.968, 95% CI 1.416, 6.221, P=0.004). Conclusions: The multi-drug resistance protein 4 variant was significantly associated with HBV DNA level suppression in chronic hepatitis B patients treated with entecavir, and therefore, patients with the rs3751333GG genotype might respond better to entecavir in the Chinese Han population.Keywords
This publication has 29 references indexed in Scilit:
- Nucleoside/nucleotide analogues in the treatment of chronic hepatitis BJournal of Antimicrobial Chemotherapy, 2011
- Ubiquitin-Mediated Proteasomal Degradation of ABC Transporters: a New Aspect of Genetic Polymorphisms and Clinical ImpactsJournal of Pharmaceutical Sciences, 2011
- The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel diseaseJournal of Gastroenterology, 2010
- The complexities of antiretroviral drug–drug interactions: role of ABC and SLC transportersTrends in Pharmacological Sciences, 2010
- Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patientsLung Cancer, 2009
- Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic ToxicityCancer Research, 2008
- Variability in human hepatic MRP4 expression: influence of cholestasis and genotypeThe Pharmacogenomics Journal, 2007
- Mrp4−/− mice have an impaired cytoprotective response in obstructive cholestasisHepatology, 2006
- Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinomaInternational Journal of Cancer, 2005
- SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism lociCell Research, 2005